997P STK11 and KEAP1 mutational status and their impact in survival outcomes in non-small cell lung cancer patients treated with immune checkpoint inhibitors: Meta-analyses of clinical trials and cohort studies

Abstract

Background: STK11 and KEAP1 mutational status can impact on survival outcomes in NSCLC patients (pts) treated with immune checkpoint inhibitors (ICIs). Through a systematic review, we identified prospective trials (PTs) and cohort studies (CSs) that evaluated the efficacy of ICIs according to STK11 and KEAP1 mutational status. We conducted meta-analyses of PTs and CSs which evaluated if these mutations could impact on survival.

The key to immunotherapy: how to choose better therapeutic biomarkers for patients with non-small cell lung cancer

“…Co-mutation of STK11 is associated with poor prognosis in KRAS G12C mutant lung adenocarcinoma patients treated with first-line ICIs [ 45 ]. In addition to co-mutations, a meta-analysis showed that mutations in STK11 and KEAP1 may adversely affect survival outcomes after ICIs in NSCLC patients [ 46 ]. Interestingly, KRAS mutations can predict PFS in NSCLC patients treated with dovalizumab after concurrent chemoradiotherapy, and mPFS was significantly shorter in patients with KRAS mutations than in patients without driver mutations [ 47 ].…”